Shares of Immunovant Inc. (IMVT), a clinical-stage immunology company developing medicines for people with autoimmune diseases, have lost more than 50% of their value from their 52-week high of $39.55, recorded last February, and trade around $19.The company has a couple of clinical trial catalysts related to its lead drug candidate, Batoclimab, to watch this quarter.Batoclimab works by targeting...
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.